Navigation Links
Tailored Treatment Boosts Kidney Cancer Survival

Study concludes one-size-fits-all therapy needs to be changed

SATURDAY, Nov. 1 (HealthDay News) -- Personalized treatment of kidney cancer patients can increase survival, according to a UCLA study of almost 1,500 patients that identified subsets of kidney cancer that behave differently and need to be treated accordingly.

The UCLA team said their findings indicate the traditional one-size-fits-all treatment approach needs to be changed.

"We have shown that not all kidney cancer patients are the same, not all localized kidney cancers are the same, and not all metastatic kidney cancers are the same," study senior author Dr. Arie Belldegrun, a professor of urology and a researcher at UCLA's Jonsson Comprehensive Cancer Center, said in a UCLA news release.

Patients with localized kidney cancer can have either low-, intermediate-, or high-risk cancers based on the chance for recurrence, the researchers found. Patients with kidney cancer that's spread (metastatic cancer) can also be categorized into similar subsets.

"Now we can base treatment decisions based on that," Belldegrun said.

Patients with localized, low-risk kidney cancer have a projected five-year survival rate of 97 percent and a 10-year survival rate of 92 percent, compared to 81 percent and 61 percent for patients with localized, intermediate-risk cancer, and 62 percent and 41 percent for patients with localized, high-risk cancer.

"All these patients with cancers that have not spread present to their doctors with presumably localized disease, and in the past, they may have been treated the same way. They need to be treated individually, according to their risk levels," Belldegrun said.

For example, the UCLA team showed that surgery alone can produce excellent outcomes in patients with localized, low-risk, kidney cancer, meaning they could be spared the harsh side effects associated with radiation or immunotherapy. But surgery alone isn't sufficient for patients with localized, high-risk kidney cancer.

Patients with metastatic, low-risk cancer should get very aggressive treatment, because there's a good chance the therapy will benefit them. But patients with metastatic, high-risk cancer may choose to decline treatment, because they'll get little or no benefit from it.

"Our paper identifies, very precisely, which patients should get which therapies," Belldegrun said.

The study was published in the Nov. 1 issue of Cancer.

More information

The American Urological Association has more about kidney cancer.

-- Robert Preidt

SOURCE: University of California, Los Angeles, news release, Nov. 1, 2008

Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Upscale Seattle-Based Skincare Clinic Expands Into California With Unique Custom Tailored Skincare Approach
2. Suboxone Fast Passing Methadone As Preferred Method Of Treatment For Opiate Detox
3. ENT doctors release national guideline on treatment for common cause of dizziness
4. Landmark UCLA study finds aggresive, personalized treatment increases kidney cancer patient survival
5. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
6. Health Secretary Raises Awareness About Diabetes; Rising Costs of Treatment
7. If metastasectomy should be performed before other treatments
8. A useful imaging modality for monitoring treatment response to hepatocellular carcinoma
9. Combo Treatment Best for Anxiety Disorder in Kids
10. Researchers identify mechanism, possible drug treatment for tumors in neurofibromatosis
11. PURE Bioscience Granted US Patent on SDC for Food Treatment
Post Your Comments:
Related Image:
Tailored Treatment Boosts Kidney Cancer Survival
(Date:11/27/2015)... ... November 27, 2015 , ... The ... prided itself for not only fulfilling the needs of advisers and clients but ... affordable price and providing top-tier customer service. However, there's always room for improvement, ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... largest, most successful and prominent nonprofit healthcare organizations in the country. They have ... with various organizations, and helped advance the healthcare industry as a whole through ...
(Date:11/27/2015)... ... ... Indosoft Inc., developer and distributor of the world-class Asterisk ... Term Support) into its Q-Suite 5.10 product line. , Making the change to ... of Asterisk that will receive not only security fixes, but feature and bug ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... ... November 26, 2015 , ... Jobs in hospital medical laboratories and in the ... healthcare staffing agency Aureus Medical Group . These fields, as well ... those searching for healthcare jobs through the company’s website, , The ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Marker Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... Israel , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused ... treatment of various clinical conditions, today announced the closing ... American Depository Shares ( ADSs ), each representing 20 ... up to 3,158,900 ADSs. The ADSs and warrants were ...
Breaking Medicine Technology: